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Comment
IGF-I AND NORMAL OR ADAPTIVE GROWTH OF BOWEL
IGF-I mediates many of the postnatal growth promoting
actions of pituitary derived growth hormone (GH) on
multiple organs between birth and puberty and during
adulthood.1 2 The bowel is now well established as an
important target organ for GH and IGF-I.1 2 GH and
IGF-I are currently being used in clinical trials to improve
bowel function in patients with short bowel syndrome.3 4
IGF-I seems to mediate many of the enterotrophic actions
of GH, which in turn increases circulating concentrations
and local expression of IGF-I in bowel.2 5 Previous studies
in transgenic mice overexpressing metallothionen pro-
moter I driven human IGF-I transgenes (MT-hIGF-I
mice) or bovine GH transgenes (MT-bGH mice) revealed
major increases in the mass of intestinal mucosa and in
small bowel length relative to wild type.5 6 MT-hIGF-I mice
have elevated circulating IGF-I, local overexpression of
IGF-I in intestine and GH deficiency.6 Despite the
deficiency in GH, MT-hIGF-I mice show similar or
increased bowel growth compared with MT-bGH mice
that have excess GH and IGF-1.6 Although studies on
MT-bGH and MT-hIGF-I mice support the concept that
IGF-I mediates most of the enterotrophic actions of GH,
they did not tackle a key issue in IGF-I physiology—that is,
the relative contributions of circulating versus locally
expressed IGF-I in mediating bowel growth. A further
limitation of the MT-hIGF-I mice is that the IGF-I trans-
gene is expressed primarily in intestinal epithelial cells
which are not the normal sites of endogenous IGF-I
expression in bowel.6 A number of lines of evidence
indicate that locally expressed, endogenous IGF-I contrib-
utes to normal or adaptive growth of bowel and is
expressed throughout human and rodent bowel.7 8 In-
creased IGF-I expression in small bowel correlates with
adaptive growth of bowel mucosa in response to refeeding9
or bowel resection,10 11 and correlates with increased
growth of mucosa and enteric smooth muscle after
myenteric denervation.12 Mesenchymal cells within the
lamina propria or external smooth muscle layers seem to be
the major sites of local expression of endogenous IGF-I in
normal bowel in vivo.8 9 12 Wang et al’s study provides direct
evidence that locally produced IGF-I can exert autocrine/
paracrine eVects and increase the mass of external smooth
muscle layers and small bowel length. That locally
expressed IGF-I increases bowel length postnatally may be
particularly relevant to patients with short bowel
syndrome.13 Systemic IGF-I increases bowel length14 but
the eVects are less dramatic than observed in SMP8-IGF-I,
MT-hIGF-I or MT-bGH mice.5 6 This diVerence may
reflect duration of IGF-I excess or may indicate particu-
larly potent eVects of locally expressed IGF-I on bowel
length. It is not clear whether increased proliferative activ-
ity of SMC in external smooth muscle layers or increased
proliferative activity within mucosal SMC or mucosal epi-
thelium, or both, increases bowel length. After bowel
resection, humans or animal models show more dramatic,
adaptive increases in mucosal thickness than in bowel
length or thickness of muscularis propria,13 15 16 which may
favour SMC in muscularis propria as major determinants
of bowel length. Future analyses of adaptive growth of
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Smooth muscle cells (SMC) of the vascular wall,
bladder, myometrium, and gastrointestinal and
respiratory tracts retain the ability to proliferate
postnatally, which enables adaptive responses to
injury, hormonal, or mechanical stimulation.
SMC growth is regulated by a number of mesen-
chymal growth factors, including insulin-like
growth factor I (IGF-I). To explore the function of
IGF-I on SMC in vivo, the mouse SMC á-actin
promotor fragment SMP8 (−1074 bp, 63 bp of 5'UT
and 2.5 kb of intron 1) was cloned upstream of rat
IGF-I cDNA, and the fusion gene microinjected
into fertilized eggs of the FVB-N mouse strain.
Mating of hemizygous mice with controls pro-
duced about 50% transgenic oVspring, with equal
sex distribution. Transgenic IGF-I mRNA expres-
sion was confined to SMC-containing tissue, with
the following hierarchy: bladder > stomach >
aorta = uterus > intestine. There was no transgene
expression in skeletal muscle, heart, or liver.
Radioimmunoassayable IGF-I content was in-
creased by 3.5- to 4-fold in aorta, and by almost
10-fold in bladder of transgenic mice at 5 and 10
wk, with no change in plasma IGF-I levels. Wet
weight of bladder, stomach, intestine, uterus, and
aorta was selectively increased, with no change in
total body or carcass weight of transgenic animals.
In situ hybridization showed that transgene
expression was exquisitely targeted to the smooth
muscle layers of the arteries, veins, bladder,
ureter, stomach, intestine, and uterus. Paracine
overproduction of IGF-I resulted in hyperplasia of
the muscular layers of these tissues, manifesting
in remarkably diVerent phenotypes in the various
SMC beds. Whereas the muscular layer of the
bladder and stomach exhibited a concentric
thickening, the SMC of the intestine and uterus
grew in a longitudinal fashion, resulting in a
marked lengthening of the small bowel and of the
uterine horns. This report describes the first suc-
cessful targeting of expression of any functional
protein capable of modifying the phenotype of
SMC in transgenic mice. IGF-I stimulates SMC
hyperplasia, leading to distinct patterns of organ
remodeling in the diVerent tissue environments.
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bowel after resection in SMP8-IGF-I mice and possibly
other transgenic models (yet to be developed) with targeted
overexpression of IGF-I in mucosal epithelium could
resolve this issue.
AUTOCRINE AND PARACRINE EFFECTS OF MESENCHYMAL CELL
DERIVED IGF-I OR OTHER GROWTH FACTORS
During embryonic development, the intestinal mesen-
chyme underlying the mucosal epithelium is essential for
normal morphogenesis, growth, and diVerentiation of
intestinal epithelium.1 18 Several growth factors, including
IGF-I, are expressed in intestinal mesenchyme.8 9 18 19
Evidence for paracrine eVects of specific factors derived
from mucosal mesenchymal cells on growth of intestinal
epithelium in vivo, particularly in the postnatal period, is
largely indirect.8 9 18 19 SMC in muscularis mucosa and
SMC or myofibroblasts in the pericryptal region or villus
core of the lamina propria express á-smooth muscle actin
(áSMA).17 18 20 Overexpression of IGF-I within these
mucosal mesenchymal cells would therefore be predicted in
SMP8-IGF-I mice. Wang et al reported high level
expression of the SMP8-IGF-I transgene in external
smooth muscle layers. More detailed and higher resolution
in situ hybridisation histochemistry analysis will be required
to determine whether the transgene is also overexpressed in
mucosal mesenchymal cells. If yes, the SMP8-IGF-I trans-
genic model could be used to assess whether IGF-I
expressed in mucosal mesenchymal cells has paracrine
eVects on neighbouring mucosal epithelium. Wang et al
reported no major diVerence in thickness of the small bowel
mucosa in SMP8-IGF-I mice compared with wild type but
this was the only measure of mucosal growth evaluated.
Additional, more detailed studies are required in small
bowel and other bowel segments to establish whether
SMP8-IGF-I mice show increased crypt cell proliferation
or altered diVerentiated function of mucosal epithelial cells.
Few promoters are currently available that permit cell
specific targeting of transgenes within bowel. The available
data in SMP8-IGF-I mice indicate that the áSMA
promoter could be used to target overexpression of other
growth factors to intestinal SMC and to analyse their
autocrine actions on SMC growth and bowel length or
function. If the SMP8-IGF-I mice do show altered growth
or function of the mucosa, this would indicate that áSMA
promoter mediated targeting of transgenes could be a gen-
erally useful approach to elucidate the role of specific
growth factors in mediating mesenchymal/epithelial inter-
actions within the bowel mucosa.
USE OF THE áSMA PROMOTER TO TARGET GROWTH FACTOR
INHIBITORS
The “gain of function” approach oVered by overexpression
of transgenes, even those targeted to specific cells, is always
subject to the criticism that excessively high or long term
overexpression may not truly reflect the physiological
function of the expressed protein. This is a potential prob-
lem with SMP8-IGF-I mice. In the future the áSMA pro-
moter may, however, be used to target inhibitors of IGF-I
action as a complementary approach to targeted IGF-I
overexpression. Targeting IGF inhibitors of intestinal mes-
enchymal cells could provide major insights into the role of
endogenous, mesenchymal cell derived IGF-I in mediating
bowel growth. A family of natural IGF binding proteins
(IGFBPs) exists, a subset of which can inhibit IGF action.1
Drs Wang and Fagin have already developed a transgenic
model with SMP8 mediated targeting of one IGFBP,
IGFBP4.21 Preliminary data are encouraging and indicate a
reverse phenotype in this model relative to SMP8-IGF-1
mice.21 There is one potential caveat to the use of the
áSMA promoter to target growth factor inhibitors. As
pointed out by Wang et al the áSMA promoter is active
throughout embryogenesis and is expressed in cardiac and
skeletal muscle in early embryogenesis. Despite this, there
was no obvious phenotype of the SMP8-IGF-I transgene at
birth. This probably reflects the fact that endogenous IGF
expression is very high in the fetus and its eVects are prob-
ably already maximal during embryonic development.
When targeting growth factor inhibitors, or even other
growth factors, the early expression of the áSMA promoter
in cardiac and skeletal muscle or expression in fetal SMC
may induce an embryonic phenotype or may complicate
the phenotype relative to that observed for IGF-I.
IGF-I AND BOWEL DISEASE
Accumulating evidence implicates IGF-I as a mediator of
mesenchymal cell responses to bowel inflammation and
associated fibrogenic complications.22 IGF-I expression is
increased locally in areas of fibrosis in the bowel of several
animal models of entercolitis and in involved bowel of
patients with Crohn’s disease.22 Fibrosis is a major
complication and cause of bowel surgery and short bowel
syndrome in patients with Crohn’s disease.13 22 The precise
cell type that mediates fibrosis in experimental enterocolitis
or Crohn’s disease has not been defined, but there is general
agreement that these cells express áSMA, suggesting a SMC
or myofibroblast phenotype.22 A subset of áSMA positive
cells are the cellular sites of increased IGF-I expression in
bowel of animal models of inflammation induced fibrosis.22
The SMP8-IGF-I mice thus show IGF-I overexpression in
the precise cell types implicated in inflammation induced
fibrosis and may be useful to assess whether constitutive
overexpression of IGF-I in áSMA positive cells exacerbates
fibrosis associated with experimental entercolitis. The com-
plementary models such as the SMP8-IGFBP4 mice or
mice with SMP8 mediated targeting of other IGF inhibitors
could also be extremely powerful models to elucidate the
extent to which endogenous IGF-I mediates inflammation
induced fibrosis. As with adaptive growth, insightful results
with the SMP8-IGF-I mice would indicate that the áSMA
promoter may have widespread application to analysis of the
roles of other factors in mesenchymal responses to
inflammation in bowel or other organs.
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